Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

NCT05942573 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

107

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

Interventions

DRUG: Serplulimab+Paclitaxel+Apatinib
DRUG: Paclitaxel±Ramucirumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital